[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Schellekens, 2012 - Google Patents

Antibodies in Cytokines: The concerted action on the antigenicity of rDNA derived pharmaceuticals

Schellekens, 2012

Document ID
8950348425342388173
Author
Schellekens H
Publication year

External Links

Snippet

This book, written by leading authors in the field, is the first to deal with all aspects of cytokine antibodies, from test methodology and standardization to biological consequences and functions. It encompasses antibodies induced by cytokines used therapeutically and …
Continue reading at books.google.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay

Similar Documents

Publication Publication Date Title
CA2185565C (en) Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases
Ross et al. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
Prümmer Treatment-induced antibodies to interleukin-2
US20130089515A1 (en) Use of IL-12 and IL-12 Antagonists in the Treatment of Autoimmune Diseases
WADHWA et al. Production of neutralizing granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) antibodies in carcinoma patients following GM‐CSF combination therapy
Turano et al. Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine.
Kivisäkk et al. Neutralising and binding anti-interferon-β-1 b (IFN-b-1 b) antibodies during IFN-β-1 b treatment of multiple sclerosis
EP0485471B1 (en) Natural human anti-gamma interferon antibodies detected and purified by synthetic peptides
ARNASON et al. Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: summary of an international workshop on anti-interferon antibodies
CN114053403A (en) Use of fusion protein in preparation of vaccine adjuvant or medicament for preventing and treating virus infection
Schellekens Antibodies in Cytokines: The concerted action on the antigenicity of rDNA derived pharmaceuticals
Khan et al. Increased binding of circulating systemic lupus erythematosus autoantibodies to recombinant interferon alpha 2b
JPH02111727A (en) Use of interleukin for immunological system time of reduction in immunoreaction
Durelli et al. Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy
Bendtzen et al. Natural and Induced Anticytokine
Yin et al. Lactoferrin protects against concanavalin A‐induced liver injury in mice
JP2000515007A (en) T cell selective interleukin-4 agonist
Turano et al. The role of human autoantibodies against γ-interferon
Bendtzen et al. Natural and induced anticytokine antibodies in humans
Steinmann et al. Low incidence of antibody formation due to long-term interferon-α 2c treatment of cancer patients
PRÜMMER et al. Anti-interferon-γ antibodies in a patient undergoing interferon-γ treatment for systemic mastocytosis
Lopez Hänninen et al. Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance
WO2014116789A1 (en) Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection
Nolte et al. Different specificities of SLE-derived and therapy-induced interferon-α antibodies
Bagnato et al. Neutralizing antibodies against endogenous interferon in myasthenia gravis patients